AIM ImmunoTech Issues Notice that an Unaffiliated Third Party and Organization are Providing False Information Related to Relationship with Company and its Affiliates

by Barry101 | Jul 18, 2023 | Press Release

OCALA, Fla., July 18, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a notice that the Company has learned that unknown person(s) and/or organization(s) are claiming to represent AIM ImmunoTech...

AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

by Barry101 | Jul 10, 2023 | Press Release

Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions Enrollment expected to be completed in Q4 2023 OCALA, Fla., July 10, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today...

AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series

by Barry101 | Jul 5, 2023 | Press Release

Live moderated video webcast on Wednesday, July 12th at 11:00 AM ETOCALA, Fla., July 05, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of...

AIM ImmunoTech Announces Publication of Positive Findings from a Pre-Clinical Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the American Journal of Cancer Research

by Barry101 | Jun 27, 2023 | Press Release

Findings support efforts in ongoing Early Access Program and upcoming clinical trials, and suggest Ampligen’s potential to reduce tumor cell growth and boost immune response in pancreatic cancer patients with sufficient tumor levels of TLR-3OCALA, Fla., June 27,...

AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer

by Barry101 | Jun 27, 2023 | Press Release

Ampligen has shown therapeutic synergies with checkpoint inhibitors, potentially increasing survival rates and efficacy Patient enrollment expected to commence before the end of 2023 OCALA, Fla., June 27, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM)...